Yesterday Biogen announced the purchase of a single phase-2 ready neuro drug from Pfizer for $75 million upfront, plus milestones of up to $515 million and royalties.
The drug was being developed by Pzifer for the treatment of cognitive symptoms in schizophrenia, and has completed phase 1 safety trials.
The value of this deal is similar to Bell Potter’s estimate for trofinetide, however I think it is closer to what Neuren could get for NNZ-2591.
https://www.fiercebiotech.com/biote...unwanted-neuro-med-for-75m-as-sell-off-starts
Add to My Watchlist
What is My Watchlist?
